• Cl-Amidine trifluoroacetate: PAD4 Inhibition for Translation

  2026-04-28

  Cl-Amidine (trifluoroacetate salt) is revolutionizing translational research by enabling precise chemical inhibition of PAD4, a central regulator of histone citrullination and gene expression. This article delivers a strategic, mechanism-driven overview, integrating recent discoveries in ribosome biogenesis and cancer cell survival with actionable guidance for deploying Cl-Amidine in advanced disease models. Researchers will gain clarity on protocol optimization, competitive benchmarking, and the translational implications of targeting PAD4 in oncology and immunology.

• GLT-1 Upregulation Mitigates Neuronal Injury Post-TBI via CB

  2026-04-28

  The reference study demonstrates that enhancing GLT-1 expression protects against neuronal apoptosis and cognitive deficits after traumatic brain injury (TBI) by inhibiting the CB1-CREB signaling cascade. This work clarifies the mechanistic link between endocannabinoid signaling and glutamate homeostasis in TBI, suggesting new therapeutic angles.

• G-1 (CAS 881639-98-1): Benchmarks for Selective GPR30 Activa

  2026-04-27

  G-1 is a potent, selective GPR30 agonist with nanomolar affinity that enables precise modulation of non-genomic estrogen signaling. Its use in cardiovascular and oncology research is backed by robust in vitro and in vivo data. G-1’s specificity and solubility profile make it a gold standard tool for studying GPR30-driven pathways.

• Human pCAR T Cells: Protocol for Synergistic Dual Co-stimula

  2026-04-27

  This protocol establishes a robust approach for generating human parallel chimeric antigen receptor (pCAR) T cells, leveraging dual co-stimulatory signaling to enhance antitumor activity. It details construct design, T cell engineering, and preclinical validation, providing a foundation for translational immunotherapy research.

• Cl-Amidine trifluoroacetate salt: Precision PAD4 Inhibition

  2026-04-26

  Cl-Amidine trifluoroacetate salt empowers translational research with robust, selective PAD4 inhibition, enabling breakthroughs in cancer, autoimmune, and septic shock models. Its proven reliability and actionable protocols, as supplied by APExBIO, help labs solve persistent challenges in citrullination assays and immune modulation.

• Optimizing Immunoassays with HyperFluor 488 Goat Anti-Human

  2026-04-25

  The HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody delivers high-sensitivity, low-background detection across immunofluorescence, Western blot, and flow cytometry platforms. Its robust Alexa Fluor 488 conjugation and rigorous purification make it a superior choice for translational research, including advanced vaccine studies and longitudinal immunomonitoring.

• GSK126 EZH2 Inhibitor: Translating PRC2 Biology Into Oncolog

  2026-04-24

  Explore the unique mechanistic and translational potential of the GSK126 EZH2 inhibitor in cancer epigenetics research. This in-depth article reveals how GSK126 advances precision oncology by targeting PRC2, with insights drawn from cutting-edge reference science.

• Indometacin Sodium Suppresses PSC Activation via COX-2 Downr

  2026-04-24

  This study demonstrates that Indometacin Sodium inhibits the proliferation and activation of human pancreatic stellate cells (PSCs) by downregulating COX-2 expression. These findings provide mechanistic insight into the potential use of COX inhibitors in targeting the tumor stroma of pancreatic ductal adenocarcinoma.

• Primary Cilia in Biliary Complications After Liver Transplan

  2026-04-23

  This study uncovers how damage to primary cilia in biliary epithelial cells under ischemic conditions drives cellular senescence, impairs regeneration, and leads to biliary complications after liver transplantation. Targeted interventions to preserve cilia or clear senescent cells are proposed as novel strategies to improve graft outcomes and reduce morbidity.

• Macrophage-EV miR-660 Drives Breast Cancer Metastasis via KL

  2026-04-23

  This study uncovers how tumor-associated macrophage-derived extracellular vesicles (EVs), carrying microRNA-660, promote breast cancer metastasis by targeting KLHL21 and activating NF-κB p65 signaling. The findings clarify a critical intercellular communication pathway in the tumor microenvironment, highlighting new molecular targets for translational oncology.

• Clarithromycin as a CYP3A Inhibitor: Advanced Workflows & Ti

  2026-04-22

  Clarithromycin stands apart as a validated CYP3A inhibitor for rigorous drug-drug interaction and pharmacokinetic studies. This guide outlines optimized experimental workflows, advanced use-cases, and practical troubleshooting tips to ensure reproducibility and data integrity in CYP3A-related research.

• Minoxidil sulphate (SKU C6513): Reliable Solutions for Vascu

  2026-04-22

  This authoritative guide examines real-world laboratory scenarios where Minoxidil sulphate (SKU C6513) addresses persistent experimental challenges in vascular biology and hair growth research. Drawing on peer-reviewed data and validated protocols, the article demonstrates how APExBIO’s high-purity formulation delivers reproducibility, sensitivity, and workflow compatibility.

• Amphotericin B (SKU B1885): Reliable Antifungal Performance

  2026-04-21

  This evidence-based article guides biomedical researchers and lab technicians through common cell assay challenges, emphasizing how Amphotericin B (SKU B1885) from APExBIO ensures reproducibility, sensitivity, and workflow safety. Drawing on peer-reviewed sources and real-world scenarios, the article provides actionable insights for deploying this polyene antifungal antibiotic in fungal infection research and cell-based assays.

• (-)-JQ1: Gold-Standard Inactive Control in BET Bromodomain R

  2026-04-21

  (-)-JQ1 is a rigorously validated JQ1 stereoisomer used as an inactive control in BET bromodomain inhibition studies. Its lack of BRD4 affinity ensures experimental specificity in epigenetics and cancer biology research. Supplied by APExBIO, (-)-JQ1 is essential for distinguishing true BET inhibitor effects from off-target phenomena.

• Quizartinib (AC220) in AML: Protocols, Applications & Troubl

  2026-04-20

  Quizartinib (AC220) is a gold-standard tool for dissecting FLT3 signaling and resistance in acute myeloid leukemia (AML) research. Discover how to optimize experimental design, maximize reproducibility, and address common challenges using this next-generation selective FLT3 inhibitor.

451 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page